254 research outputs found
D87 Inno-preneurial spaces- Inno-preneurship Methodology for Inno-preneurial Spaces
No full textThe Inno-preneurship Methodology for Inno-preneurship Spaces aims to create a
common framework for the virtual and physical Inno-preneurship Spaces existing
within the ENGAGE.EU alliance, define their main characteristics on the basis of the
existing spaces within the ENGAGE.EU alliance and set a common baseline
methodology for their functioning to be tested in a first iteration of its rollout
La versione neoaramaica di un inno siriaco per Natale
No full textIl testo qui pubblicato è la versione neoaramaica di un inno natalizio molto popolare tra i cristiani di tradizione siriaca. L’innografo ricostruisce le parole che la madre di Gesù cantava a Betlemme al figlio appena nato. La “ninna nanna” che l’autore sostiene di aver carpito dalla voce incantevole di Maria è in realtà un prodigio di retorica teologica; non c’è nulla di psicologico o di realistico nel canto della madre per il suo neonato, anche se la dolcezza della scena evocata dall’inno deve aver avuto un ruolo non secondario nel suo successo.
Per favorire il confronto tra le versioni classiche e quella neoaramaica, due testi sono proposti in sinossi, neoaramaico nella colonna di destra e siriaco classico nella colonna di sinistra. Il testo siriaco classico rappresenta di fatto un abbozzo di edizione critica delle versioni a stampa finora edite.
La versione neoaramaica, finora inedita, è conservata da un codice del British Museum e riflette il tipo di lingua descritto da Edward Sachau come koine neoaramaica parlata a Mosul verso la fine del XIX secolo. Da un punto di vista letterario, il testo si inserisce nella tradizione e nel gusto della poesia religiosa popolare dei caldei del Nord Iraq.
Si tratta infatti della traduzione di un testo liturgico classico nel linguaggio poetico moderno, il cui utilizzo da parte di dotti pastori della chiesa sira orientale è attestato dalla fine del XVI secolo.
Il testo neoaramaico è accompagnato dalla traduzione italiana dell'editore e araba del copista; segue puntuale commento linguistico-dialettologico e letterario
La versione neoaramaica di un inno siriaco per Natale
No full textIl testo qui pubblicato è la versione neoaramaica di un inno natalizio molto popolare tra i cristiani di tradizione siriaca. L’innografo ricostruisce le parole che la madre di Gesù cantava a Betlemme al figlio appena nato. La “ninna nanna” che l’autore sostiene di aver carpito dalla voce incantevole di Maria è in realtà un prodigio di retorica teologica; non c’è nulla di psicologico o di realistico nel canto della madre per il suo neonato, anche se la dolcezza della scena evocata dall’inno deve aver avuto un ruolo non secondario nel suo successo.
Per favorire il confronto tra le versioni classiche e quella neoaramaica, due testi sono proposti in sinossi, neoaramaico nella colonna di destra e siriaco classico nella colonna di sinistra. Il testo siriaco classico rappresenta di fatto un abbozzo di edizione critica delle versioni a stampa finora edite.
La versione neoaramaica, finora inedita, è conservata da un codice del British Museum e riflette il tipo di lingua descritto da Edward Sachau come koine neoaramaica parlata a Mosul verso la fine del XIX secolo. Da un punto di vista letterario, il testo si inserisce nella tradizione e nel gusto della poesia religiosa popolare dei caldei del Nord Iraq.
Si tratta infatti della traduzione di un testo liturgico classico nel linguaggio poetico moderno, il cui utilizzo da parte di dotti pastori della chiesa sira orientale è attestato dalla fine del XVI secolo.
Il testo neoaramaico è accompagnato dalla traduzione italiana dell'editore e araba del copista; segue puntuale commento linguistico-dialettologico e letterario
Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside—Part 1
No full textAtherosclerosis, a complex metabolic-immune disease characterized by chronic inflammation driven by the buildup of lipid-rich plaques within arterial walls, has emerged as a pivotal factor in the intricate interplay between cancer and cardiovascular disease. This bidirectional relationship, marked by shared risk factors and pathophysiological mechanisms, underscores the need for a comprehensive understanding of how these two formidable health challenges intersect and influence each other. Cancer and its treatments can contribute to the progression of atherosclerosis, while atherosclerosis, with its inflammatory microenvironment, can exert profound effects on cancer development and outcomes. Both cancer and cardiovascular disease involve intricate interactions between general and personal exposomes. In this review, we aim to summarize the state of the art of translational data and try to show how oncologic studies on cardiotoxicity can broaden our knowledge of crucial pathways in cardiovascular biology and exert a positive impact on precision cardiology and cardio-oncology
Pretreatment lung immune prognostic index as biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab
No full textBackground: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-small-cell lung cancer patients receiving pembrolizumab. Patients & methods: We retrospectively identified 117 patients, divided into 3 prognostic groups according to LIPI score. For each patient, we evaluated 1-year overall survival (OS) and progression-free survival rate. C-statistic and survival receiver operating characteristic curves were used to study discrimination of LIPI. Results: After a median follow-up of 11.7 months, 1-year OS rate was 60.1%, 35.3% and 28.6%, while 1-year progression-free survival rate was 39.1%, 20.6% and 14.3% in good, intermediate and poor LIPI groups, respectively (p < 0.001). The c-statistic and area under the curve of LIPI were 0.63 and 0.662 for OS and 1-year OS, respectively. Conclusions: Higher LIPI score is related to worse survival in advanced non-small-cell lung cancer patients treated with first-line pembrolizumab. However, based on c-statistic and area under the curve, LIPI does not represent a good prognostic survival model
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
No full textGut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs
Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
No full textIn the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and the activity of sotorasib in the setting of brain metastases should be further investigated. Here we report the case of a KRAS p.G12C mutant NSCLC patient with three brain metastases, of whom one was untreated and the other two had progressed after radiotherapy with symptoms requiring steroids, that responded to sotorasib. Our report suggests that sotorasib may be active against untreated or progressive brain metastases, supporting further evaluation of sotorasib in this setting
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer.
No full textMaria Di Bartolomeo,1 Claudia Maggi,1 Francesca Ricchini,1 Filippo Pietrantonio,1 Roberto Iacovelli,1 Filippo de Braud,1 Alessandro Inno2 1Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 2Department of Medical Oncology, Sacro Cuore-Don Calabria Hospital, Negrar, Italy Abstract: Metastatic colorectal cancer (mCRC), like many cancers, is primarily a disease of elderly people. Despite this prevalence, such patients are often excluded from randomized trials or represent a minority of enrolled patients. Moreover, the criteria for establishing benefit or side effects of treatment strategies in this population are uncertain and not well recognized. Bevacizumab improves the outcome of mCRC when used in combination with standard first-line and second-line chemotherapy and beyond the first disease progression when given with a chemotherapy backbone different from that used in the precedent line. The particular toxicity profile of this antiangiogenesis agent (in particular hypertension, thromboembolic events, hemorrhage, and renal failure) may discourage its use in elderly patients with comorbidities. Data from subgroup analyses of randomized trials and the results of recent cohort studies suggest a significant benefit from the addition of bevacizumab to standard chemotherapy for elderly patients comparable with that observed in younger patients, except for the increased risk for thromboembolic events. Age alone should not be a barrier to use of bevacizumab, and further research with a more complete geriatric assessment should investigate the role of bevacizumab in elderly patients with mCRC to avoid undertreatment of this patient population due to a ­historical conservative approach. Keywords: bevacizumab, elderly, metastatic colorectal cancer, antivascular treatment, revie
Partnering as a strategy to approach new markets : case Anders Inno
No full textThis thesis was done for Anders Inno Oy, a Finnish small and medium sized enterprise from Turku, interested in widening their operations by approaching international markets.
This thesis was based on the applied thesis model. The purpose of this thesis was to analyse the process of partnering as a strategy in the case of Anders Inno Oy with a strong focus on trust and commitment as part of the partnering process. The research method was to investigate and analyse the factors of commitment and trust in partnerships and implement partnering as a potential strategy for Anders Inno to approach the German markets.
The first part of this thesis was to briefly illustrate the case background and circumstances of the starting situation of the project at the time the author was assigned. The second part consisted out of discussing partnering in general, as well as the part of commitment and the relationship between trust and commitment in particular. The third part was to evaluate the partnering approach by its general adaptability to this case, distinctions in its application and matters of general application to a case.
The research process of this thesis showed that partnering can bring a lot advantages to companies when understood in the right way and implemented accordingly. The main conclusions were that partnering could be the ideal strategy for reaching previously unattainable markets. However, dependent on mutual willingness and need and therefore not always easily establish able
- …
